Tizanidine-d4 (hydrochloride) |
| Catalog No.GC48183 |
An internal standard for the quantification of tizanidine
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1188263-51-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Tizanidine-d4 is intended for use as an internal standard for the quantification of tizanidine by GC- or LC-MS. Tizanidine is an α2-adrenergic receptor (α2-AR) agonist.1 Administration of tizanidine reduces neuronal excitation induced by noxious stimuli and depresses spontaneous neuronal firing in anesthetized cats. Tizanidine-induced neuronal depression is reversed by the selective α2-AR antagonist RX781094 but not the α1-AR antagonists prazosin and WB-4101. It acts as a muscle relaxant that inhibits α- and γ-rigidity in rats, reflex muscle tone in rabbits, and the linguomadibular reflex in cats without sedative, hemodynamic, or neurochemical effects.2 Formulations containing tizanidine have been used for the treatment of stiff-person syndrome and to improve gait function in patients with incomplete spinal cord injuries.3,4
1.Davies, J., and Quinlan, J.E.Selective inhibition of responses of feline dorsal horn neurons to noxious cutaneous stimuli by tizanidine (DS103-282) and noradrenaline: Involvement of α2-adrenoceptorsNeuroscience16(3)673-682(1985) 2.Sayers, A.C., BÜrki, H.R., and Eichenberger, E.The pharmacology of 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole (DS 103-282), a novel myotonolytic agentArzneimittelforschung30(5)793-803(1980) 3.Meinck, H.-M., Ricker, K., and Conrad, B.The stiff-man syndrome: New pathophysiological aspects from abnormal exteroceptive reflexes and the response to clomipramine, clonidine, and tizanidineJ. Neurol. Neurosurg. Psychiatry47(3)280-287(1984) 4.Duffell, L.D., Brown, G.L., and Mirbagheri, M.M.Facilitatory effects of anti-spastic medication on robotic locomotor training in people with chronic incomplete spinal cord injuryJ. Neuroeng. Rehabil.1229(2015)
| Cas No. | 1188263-51-5 | SDF | |
| Canonical SMILES | ClC1=C(NC2=NC([2H])([2H])C([2H])([2H])N2)C3=NSN=C3C=C1.Cl | ||
| Formula | C9H4ClD4N5S.HCl | M.Wt | 294.2 |
| Solubility | Methanol: soluble,Water: soluble | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.399 mL | 16.9952 mL | 33.9905 mL |
| 5 mM | 679.8 μL | 3.399 mL | 6.7981 mL |
| 10 mM | 339.9 μL | 1.6995 mL | 3.399 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 6 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *